Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study

Table 4 pCR of neoadjuvant chemotherapy

pCR	PLD group n (%)	Epirubicin group n (%)	P value
Before PSM, n	65	130
bpCR	16 (24.6%)	20 (15.4%)	0.1173
tpCR	9 (13.9%)	12 (9.2%)	0.3270
After PSM, n	43	43
bpCR	11 (25.6%)	6 (14.0%)	0.1758
tpCR	5 (11.6%)	3 (7.0%)	0.4578

PLD Pegylated liposomal doxorubicin, tpCR Total pathological complete response, bpCR Breast pathological complete response

ISSN: 1471-2407